Product Description
Mechanisms of Action: CCR9 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Crohn Disease
Phase 2: Crohn Disease|Colitis, Ulcerative|Celiac Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Open label extension study | P3 |
Terminated |
Crohn Disease |
2013-10-29 |
|
| 2010-022383-12 | P3 |
Terminated |
Crohn Disease |
2013-10-23 |
|
| SHIELD-2 | P3 |
Terminated |
Crohn Disease |
2013-10-23 |
|
| SHIELD-4 | P3 |
Terminated |
Crohn Disease |
2013-10-17 |